首页 > 最新文献

Cancer Immunology, Immunotherapy最新文献

英文 中文
The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells. PD-L1在肿瘤衍生外泌体上的表达增强了αCD3 × αPD-L1双特异性抗体武装T细胞的浸润和抗肿瘤活性。
IF 4.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-08-06 DOI: 10.1007/s00262-024-03785-4
Jaewon Cho, Nara Tae, Yujeong Song, Chae-Won Kim, Seung-Joo Lee, Jae-Hee Ahn, Kwang-Ho Lee, Byung-Hyun Lee, Byung Soo Kim, Sun-Young Chang, Dae Hee Kim, Hyun-Jeong Ko

Anti-cluster of differentiation (CD) 3 × α programmed death-ligand 1 (PD-L1) bispecific T-cell engager (BsTE)-bound T-cells (BsTE:T) are a promising new cancer treatment agent. However, the mechanisms of action of bispecific antibody-armed activated T-cells are poorly understood. Therefore, this study aimed to investigate the anti-tumor mechanism and efficacy of BsTE:T. The BsTE:T migration was assessed in vivo and in vitro using syngeneic and xenogeneic tumor models, flow cytometry, immunofluorescence staining, transwell migration assays, microfluidic chips, Exo View R100, western blotting, and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 technology. In murine B16 melanoma, MC38 colon cancer, and human multiple myeloma cells, BsTE:T exhibited superior tumor elimination relative to that of T-cells or BsTE alone. Moreover, BsTE:T migration into tumors was significantly enhanced owing to the presence of PD-L1 in tumor cells and secretion of PD-L1-containing exosomes. Furthermore, increased infiltration of CD44highCD62Llow effector memory CD8+ T-cells into tumors was closely associated with the anti-tumor effect of BsTE:T. Therefore, BsTE:T is an innovative potential anti-tumor therapy, and exosomal PD-L1 plays a crucial role both in vitro and in vivo in the anti-tumor activity of BsTE:T.

抗分化簇(CD)3 × α程序性死亡配体 1(PD-L1)双特异性 T 细胞吸引子(BsTE)结合 T 细胞(BsTE:T)是一种很有前景的新型癌症治疗药物。然而,人们对双特异性抗体修饰的活化 T 细胞的作用机制知之甚少。因此,本研究旨在探讨 BsTE:T 的抗肿瘤机制和疗效。本研究利用合成肿瘤模型和异种肿瘤模型、流式细胞术、免疫荧光染色、Transwell迁移试验、微流控芯片、Exo View R100、Western印迹和聚类规则间距短回文重复序列(CRISPR)/CRISPR相关蛋白9技术,对BsTE:T的体内和体外迁移进行了评估。在小鼠 B16 黑色素瘤、MC38 结肠癌和人类多发性骨髓瘤细胞中,BsTE:T 的肿瘤消除效果优于 T 细胞或 BsTE 本身。此外,由于肿瘤细胞中存在 PD-L1 和分泌含 PD-L1 的外泌体,BsTE:T 向肿瘤的迁移明显增强。此外,CD44highCD62Llow效应记忆CD8+T细胞浸润肿瘤的增加与BsTE:T的抗肿瘤作用密切相关。因此,BsTE:T 是一种具有创新潜力的抗肿瘤疗法,外泌体 PD-L1 在 BsTE:T 的体外和体内抗肿瘤活性中发挥着关键作用。
{"title":"The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells.","authors":"Jaewon Cho, Nara Tae, Yujeong Song, Chae-Won Kim, Seung-Joo Lee, Jae-Hee Ahn, Kwang-Ho Lee, Byung-Hyun Lee, Byung Soo Kim, Sun-Young Chang, Dae Hee Kim, Hyun-Jeong Ko","doi":"10.1007/s00262-024-03785-4","DOIUrl":"10.1007/s00262-024-03785-4","url":null,"abstract":"<p><p>Anti-cluster of differentiation (CD) 3 × α programmed death-ligand 1 (PD-L1) bispecific T-cell engager (BsTE)-bound T-cells (BsTE:T) are a promising new cancer treatment agent. However, the mechanisms of action of bispecific antibody-armed activated T-cells are poorly understood. Therefore, this study aimed to investigate the anti-tumor mechanism and efficacy of BsTE:T. The BsTE:T migration was assessed in vivo and in vitro using syngeneic and xenogeneic tumor models, flow cytometry, immunofluorescence staining, transwell migration assays, microfluidic chips, Exo View R100, western blotting, and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 technology. In murine B16 melanoma, MC38 colon cancer, and human multiple myeloma cells, BsTE:T exhibited superior tumor elimination relative to that of T-cells or BsTE alone. Moreover, BsTE:T migration into tumors was significantly enhanced owing to the presence of PD-L1 in tumor cells and secretion of PD-L1-containing exosomes. Furthermore, increased infiltration of CD44<sup>high</sup>CD62L<sup>low</sup> effector memory CD8<sup>+</sup> T-cells into tumors was closely associated with the anti-tumor effect of BsTE:T. Therefore, BsTE:T is an innovative potential anti-tumor therapy, and exosomal PD-L1 plays a crucial role both in vitro and in vivo in the anti-tumor activity of BsTE:T.</p>","PeriodicalId":9595,"journal":{"name":"Cancer Immunology, Immunotherapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial. 用KN046、化疗和姑息性放疗一线治疗晚期食管鳞状细胞癌:一项开放标签、剂量升级和剂量扩大的Ib期试验。
IF 4.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-08-06 DOI: 10.1007/s00262-024-03769-4
Qi Zhao, Xi Su, Jiao Xue, Yandong Liu, Jiaxing Zhu, Xuwei Cai, Songbing Qin

There is growing evidence to suggest that radiotherapy might enhance the efficacy of immunotherapy. This study aimed to assess the possibility of KN046, a bispecific antibody targeting PD-L1 and CTLA-4, combined with chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma (ESCC). In this open-label, phase Ib trial, patients with advanced ESCC were administered chemotherapy with palliative radiotherapy, and KN046 in the predefined escalation dosages of 1, 3, or 5 mg/kg (every 3 weeks during chemotherapy cycles and every 2 weeks during KN046 maintenance). The chemotherapy regimen constituted cisplatin (75 mg/m2 i.v., d1) and paclitaxel (135-175 mg/m2 ivgtt., d1). Radiotherapy specifics, including site, timing, dose, and fragmentation pattern, were at the investigator's discretion. The primary outcome was dose-limiting toxicity (DLT). From May 2019 to April 2021, 25 patients were enrolled across the dosage groups: 3 in 1 mg/kg, 12 in 3 mg/kg, and 10 in 5 mg/kg. No DLT was observed during the dose escalation. The objective response rate was 41.7% (95%CI 22.1-63.4), while the disease control rate was 87.5% (95%CI 67.6-97.3). At a median follow-up of 11.8 months, the median progression-free survival was 7.8 months (95%CI 5.2-9.7) and median overall survival was 15.9 months (95%CI 8.4-NE). Serious adverse events were reported in 48.0% of patients, predominantly leukopenia (16%), immune-mediated enterocolitis (12%), immune-mediated pneumonitis (8%), and neutropenia (8%). Combining KN046 with chemotherapy and palliative radiotherapy might be feasible, showing a favorable safety profile and notable efficacy in advanced ESCC patients.

越来越多的证据表明,放疗可提高免疫疗法的疗效。本研究旨在评估针对PD-L1和CTLA-4的双特异性抗体KN046与化疗和姑息性放疗联合治疗晚期食管鳞状细胞癌(ESCC)的可能性。在这项开放标签的Ib期试验中,晚期食管鳞癌患者接受了化疗和姑息性放疗,并按照预定的升级剂量1、3或5 mg/kg服用了KN046(化疗周期内每3周服用一次,KN046维持治疗期间每2周服用一次)。化疗方案包括顺铂(75 mg/m2 i.v.,d1)和紫杉醇(135-175 mg/m2 ivgtt.,d1)。放疗的具体细节,包括部位、时间、剂量和碎裂模式,由研究者自行决定。主要结果是剂量限制性毒性(DLT)。从2019年5月到2021年4月,各剂量组共招募了25名患者:1毫克/千克组3人、3毫克/千克组12人、5毫克/千克组10人。在剂量递增期间,未观察到任何 DLT。客观反应率为41.7%(95%CI 22.1-63.4),疾病控制率为87.5%(95%CI 67.6-97.3)。中位随访时间为11.8个月,无进展生存期中位数为7.8个月(95%CI 5.2-9.7),总生存期中位数为15.9个月(95%CI 8.4-NE)。48.0%的患者报告了严重不良事件,主要是白细胞减少(16%)、免疫介导的小肠结肠炎(12%)、免疫介导的肺炎(8%)和中性粒细胞减少(8%)。将KN046与化疗和姑息性放疗联合使用可能是可行的,它在晚期ESCC患者中显示出良好的安全性和显著的疗效。
{"title":"First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial.","authors":"Qi Zhao, Xi Su, Jiao Xue, Yandong Liu, Jiaxing Zhu, Xuwei Cai, Songbing Qin","doi":"10.1007/s00262-024-03769-4","DOIUrl":"10.1007/s00262-024-03769-4","url":null,"abstract":"<p><p>There is growing evidence to suggest that radiotherapy might enhance the efficacy of immunotherapy. This study aimed to assess the possibility of KN046, a bispecific antibody targeting PD-L1 and CTLA-4, combined with chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma (ESCC). In this open-label, phase Ib trial, patients with advanced ESCC were administered chemotherapy with palliative radiotherapy, and KN046 in the predefined escalation dosages of 1, 3, or 5 mg/kg (every 3 weeks during chemotherapy cycles and every 2 weeks during KN046 maintenance). The chemotherapy regimen constituted cisplatin (75 mg/m<sup>2</sup> i.v., d1) and paclitaxel (135-175 mg/m<sup>2</sup> ivgtt., d1). Radiotherapy specifics, including site, timing, dose, and fragmentation pattern, were at the investigator's discretion. The primary outcome was dose-limiting toxicity (DLT). From May 2019 to April 2021, 25 patients were enrolled across the dosage groups: 3 in 1 mg/kg, 12 in 3 mg/kg, and 10 in 5 mg/kg. No DLT was observed during the dose escalation. The objective response rate was 41.7% (95%CI 22.1-63.4), while the disease control rate was 87.5% (95%CI 67.6-97.3). At a median follow-up of 11.8 months, the median progression-free survival was 7.8 months (95%CI 5.2-9.7) and median overall survival was 15.9 months (95%CI 8.4-NE). Serious adverse events were reported in 48.0% of patients, predominantly leukopenia (16%), immune-mediated enterocolitis (12%), immune-mediated pneumonitis (8%), and neutropenia (8%). Combining KN046 with chemotherapy and palliative radiotherapy might be feasible, showing a favorable safety profile and notable efficacy in advanced ESCC patients.</p>","PeriodicalId":9595,"journal":{"name":"Cancer Immunology, Immunotherapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer. 与HER-2阴性转移性乳腺癌患者对艾瑞布林和尼夫单抗联合疗法的反应相关的基因组和转录组图谱
IF 4.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-08-06 DOI: 10.1007/s00262-024-03782-7
Changhee Park, Koung Jin Suh, Se Hyun Kim, Kyung-Hun Lee, Seock-Ah Im, Min Hwan Kim, Joohyuk Sohn, Jae Ho Jeong, Kyung Hae Jung, Kyoung Eun Lee, Yeon Hee Park, Hee-Jun Kim, Eun Kyung Cho, In Sil Choi, Seung-Jae Noh, Inkyung Shin, Dae-Yeon Cho, Jee Hyun Kim

Background: Biomarkers for predicting response to the immunotherapy and chemotherapy combination in breast cancer patients are not established. In this study, we report exploratory genomic and transcriptomic analyses of pretreatment tumor tissues from patients enrolled in phase II clinical trial of a combination of eribulin and nivolumab for HER-2-negative metastatic breast cancer (MBC) (KORNELIA trial, NCT04061863).

Methods: We analyzed associations between tumor molecular profiles based on genomic (n = 76) and transcriptomic data (n = 58) and therapeutic efficacy. Patients who achieved progression-free survival (PFS) ≥ 6 months were defined as PFS6-responders and PFS6-nonresponders otherwise.

Findings: Analyses on tumor mutation burden (TMB) showed a tendency toward a favorable effect on efficacy, while several analyses related to homologous recombination deficiency (HRD) indicated a potentially negative impact on efficacy. Patients harboring TP53 mutations showed significantly poor PFS6 rate and PFS, which correlated with the enrichment of cell cycle-related signatures in PFS6-nonresponders. High antigen presentation gene set enrichment scores (≥ median) were significantly associated with longer PFS. Naïve B-cell and plasma cell proportions were considerably higher in long responders (≥ 18 months).

Interpretation: Genomic features including TMB, HRD, and TP53 mutations and transcriptomic features related to immune cell profiles and cell cycle may distinguish responders. Our findings provide insights for further exploring the combination regimen and its biomarkers in these tumors.

背景预测乳腺癌患者对免疫疗法和化疗联合疗法反应的生物标志物尚未确立。在本研究中,我们报告了对参加艾瑞布林和尼夫单抗联合治疗HER-2阴性转移性乳腺癌(MBC)II期临床试验(KORNELIA试验,NCT04061863)的患者的预处理肿瘤组织进行的探索性基因组学和转录组学分析:我们分析了基于基因组(n = 76)和转录组数据(n = 58)的肿瘤分子特征与疗效之间的关联。无进展生存期(PFS)≥6个月的患者定义为PFS6应答者,否则定义为PFS6非应答者:对肿瘤突变负荷(TMB)的分析表明,肿瘤突变负荷对疗效有有利影响,而与同源重组缺陷(HRD)相关的几项分析表明,肿瘤突变负荷对疗效有潜在的负面影响。携带TP53突变的患者的PFS6率和PFS明显较低,这与PFS6无反应者中细胞周期相关特征的富集有关。高抗原呈递基因组富集得分(≥中位数)与较长的PFS显著相关。长期应答者(≥ 18 个月)的新生 B 细胞和浆细胞比例明显更高:解读:包括TMB、HRD和TP53突变在内的基因组特征以及与免疫细胞特征和细胞周期相关的转录组特征可区分应答者。我们的研究结果为进一步探索这些肿瘤的联合治疗方案及其生物标志物提供了启示。
{"title":"Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.","authors":"Changhee Park, Koung Jin Suh, Se Hyun Kim, Kyung-Hun Lee, Seock-Ah Im, Min Hwan Kim, Joohyuk Sohn, Jae Ho Jeong, Kyung Hae Jung, Kyoung Eun Lee, Yeon Hee Park, Hee-Jun Kim, Eun Kyung Cho, In Sil Choi, Seung-Jae Noh, Inkyung Shin, Dae-Yeon Cho, Jee Hyun Kim","doi":"10.1007/s00262-024-03782-7","DOIUrl":"10.1007/s00262-024-03782-7","url":null,"abstract":"<p><strong>Background: </strong>Biomarkers for predicting response to the immunotherapy and chemotherapy combination in breast cancer patients are not established. In this study, we report exploratory genomic and transcriptomic analyses of pretreatment tumor tissues from patients enrolled in phase II clinical trial of a combination of eribulin and nivolumab for HER-2-negative metastatic breast cancer (MBC) (KORNELIA trial, NCT04061863).</p><p><strong>Methods: </strong>We analyzed associations between tumor molecular profiles based on genomic (n = 76) and transcriptomic data (n = 58) and therapeutic efficacy. Patients who achieved progression-free survival (PFS) ≥ 6 months were defined as PFS6-responders and PFS6-nonresponders otherwise.</p><p><strong>Findings: </strong>Analyses on tumor mutation burden (TMB) showed a tendency toward a favorable effect on efficacy, while several analyses related to homologous recombination deficiency (HRD) indicated a potentially negative impact on efficacy. Patients harboring TP53 mutations showed significantly poor PFS6 rate and PFS, which correlated with the enrichment of cell cycle-related signatures in PFS6-nonresponders. High antigen presentation gene set enrichment scores (≥ median) were significantly associated with longer PFS. Naïve B-cell and plasma cell proportions were considerably higher in long responders (≥ 18 months).</p><p><strong>Interpretation: </strong>Genomic features including TMB, HRD, and TP53 mutations and transcriptomic features related to immune cell profiles and cell cycle may distinguish responders. Our findings provide insights for further exploring the combination regimen and its biomarkers in these tumors.</p>","PeriodicalId":9595,"journal":{"name":"Cancer Immunology, Immunotherapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking the potential of HHLA2: identifying functional immune infiltrating cells in the tumor microenvironment and predicting clinical outcomes in laryngeal squamous cell carcinoma. 挖掘 HHLA2 的潜力:识别肿瘤微环境中的功能性免疫浸润细胞并预测喉鳞状细胞癌的临床预后。
IF 4.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-08-06 DOI: 10.1007/s00262-024-03791-6
Wenjing Li, Jianqing You, Haixiang Xue, Yi Liu, Junjun Chen, Xiao Zheng, Lujun Chen, Changping Wu
<p><strong>Background: </strong>HHLA2 (human endogenous retrovirus-H long terminal repeat-associating protein 2) represents a recently identified member of the B7 immune checkpoint family, characterized by limited expression in normal tissues but notable overexpression in various cancer types. Nevertheless, the precise function and interaction with immune cells remain poorly understood, particularly in laryngeal squamous cell carcinoma (LSCC). This investigation endeavored to elucidate the biological significance of HHLA2 within the tumor microenvironment of human LSCC tissues and delineate the clinical relevance and functional roles of HHLA2 in LSCC pathogenesis.</p><p><strong>Methods: </strong>Through multiplexed immunohistochemistry analyses conducted on tissue microarrays sourced from LSCC patients (n = 72), the analysis was executed to assess the expression levels of HHLA2, density and spatial patterns of CD68<sup>+</sup>HLA-DR<sup>+</sup>CD163<sup>-</sup> (M1 macrophages), CTLA-4<sup>+</sup>CD4<sup>+</sup>FoxP3<sup>+</sup> (CTLA-4<sup>+</sup>Treg cells), CTLA-4<sup>+</sup>CD4<sup>+</sup>FoxP3<sup>-</sup> (CTLA-4<sup>+</sup>Tcon cells), exhausted CD8<sup>+</sup>T cells, and terminally exhausted CD8<sup>+</sup>T cells in LSCC tissues. Survival analysis was conducted to evaluate the prognostic significance of HHLA2 and these immune checkpoints or immune cell populations, employing COX regression analysis to identify independent prognostic factors.</p><p><strong>Results: </strong>Kaplan-Meier (K-M) survival curves revealed a significant association between HHLA2 expression and overall survival (OS) in LSCC. Elevated levels of HHLA2 were linked to reduced patient survival, indicating its potential as a prognostic marker (HR: 3.230, 95%CI 0.9205-11.34, P = 0.0067). Notably, increased infiltration of CD68<sup>+</sup> cells (total macrophages), STING<sup>+</sup>CD68<sup>+</sup>HLA-DR<sup>+</sup>CD163<sup>-</sup> (STING<sup>+</sup>M1 macrophages), CTLA-4<sup>+</sup>CD4<sup>+</sup>FoxP3<sup>+</sup>, CTLA-4<sup>+</sup>CD4<sup>+</sup>FoxP3<sup>-</sup>, PD-1<sup>+</sup>LAG-3<sup>+</sup>CD8<sup>+</sup>T cells, and PD-1<sup>+</sup>LAG-3<sup>+</sup>TIM-3<sup>+</sup>CD8<sup>+</sup>T cells strongly linked to poorer survival outcomes (P < 0.05). A discernible trend was observed between the levels of these immune cell populations, STING<sup>+</sup>CD68<sup>+</sup> (STING<sup>+</sup> total macrophages), CD68<sup>+</sup>HLA-DR<sup>+</sup>CD163<sup>-</sup>, STING<sup>+</sup>CD68<sup>+</sup>CD163<sup>+</sup>HLA-DR<sup>-</sup> (STING<sup>+</sup>M2 macrophages), PD-1<sup>+</sup>LAG-3<sup>-</sup>CD8<sup>+</sup>T cells, PD-1<sup>+</sup>TIM-3<sup>+</sup>CD8<sup>+</sup>T cells, and PD-1<sup>+</sup>LAG-3<sup>+</sup>TIM-3<sup>-</sup>CD8<sup>+</sup>T cells and prognosis. Importantly, multivariate COX analysis identified HHLA2 as an independent predictive factor for OS in LSCC patients (HR = 3.86, 95% CI 1.08-13.80, P = 0.038). This underscored the potential of HHLA2 as a c
背景:HHLA2(人类内源性逆转录病毒-H长末端重复相关蛋白2)是最近发现的B7免疫检查点家族成员,其特点是在正常组织中表达有限,但在各种癌症类型中明显过表达。然而,该蛋白的确切功能以及与免疫细胞的相互作用仍鲜为人知,尤其是在喉鳞状细胞癌(LSCC)中。本研究旨在阐明HHLA2在人类LSCC组织肿瘤微环境中的生物学意义,并阐明HHLA2在LSCC发病机制中的临床意义和功能作用:通过对来自LSCC患者(n = 72)的组织芯片进行多重免疫组化分析,评估HHLA2的表达水平、CD68+HLA-DR+CD163-(M1巨噬细胞)、CTLA-4+CD4+FoxP3+(CTLA-4+Treg细胞)、CTLA-4+CD4+FoxP3-(CTLA-4+Tcon细胞)、衰竭CD8+T细胞和终末衰竭CD8+T细胞的密度和空间模式。为了评估HHLA2和这些免疫检查点或免疫细胞群的预后意义,我们采用COX回归分析来确定独立的预后因素,并进行了生存分析:结果:Kaplan-Meier(K-M)生存曲线显示,HHLA2的表达与LSCC的总生存率(OS)之间存在显著关联。HHLA2水平升高与患者生存率降低有关,这表明它有可能成为预后标志物(HR:3.230,95%CI 0.9205-11.34,P = 0.0067)。值得注意的是,CD68+细胞(总巨噬细胞)、STING+CD68+HLA-DR+CD163-细胞(STING+M1巨噬细胞)、CTLA-4+CD4+FoxP3+细胞、CTLA-4+CD4+FoxP3-细胞、PD-1+LAG-3+CD8+T细胞和PD-1+LAG-3+CD8+T细胞的浸润增加、P+CD68+(STING+总巨噬细胞)、CD68+HLA-DR+CD163-、STING+CD68+CD163+HLA-DR-(STING+M2 巨噬细胞)、PD-1+LAG-3-CD8+T 细胞、PD-1+TIM-3+CD8+T 细胞和 PD-1+LAG-3+TIM-3-CD8+T 细胞与预后密切相关。重要的是,多变量 COX 分析发现 HHLA2 是 LSCC 患者 OS 的独立预测因素(HR = 3.86,95% CI 1.08-13.80,P = 0.038)。这凸显了HHLA2作为预测LSCC患者预后的关键标志物的潜力:结论:HHLA2是评估LSCC患者OS的不利预后生物标志物。与其他免疫检查点相比,HHLA2对LSCC患者的预后具有更高的预测效力。
{"title":"Unlocking the potential of HHLA2: identifying functional immune infiltrating cells in the tumor microenvironment and predicting clinical outcomes in laryngeal squamous cell carcinoma.","authors":"Wenjing Li, Jianqing You, Haixiang Xue, Yi Liu, Junjun Chen, Xiao Zheng, Lujun Chen, Changping Wu","doi":"10.1007/s00262-024-03791-6","DOIUrl":"10.1007/s00262-024-03791-6","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;HHLA2 (human endogenous retrovirus-H long terminal repeat-associating protein 2) represents a recently identified member of the B7 immune checkpoint family, characterized by limited expression in normal tissues but notable overexpression in various cancer types. Nevertheless, the precise function and interaction with immune cells remain poorly understood, particularly in laryngeal squamous cell carcinoma (LSCC). This investigation endeavored to elucidate the biological significance of HHLA2 within the tumor microenvironment of human LSCC tissues and delineate the clinical relevance and functional roles of HHLA2 in LSCC pathogenesis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Through multiplexed immunohistochemistry analyses conducted on tissue microarrays sourced from LSCC patients (n = 72), the analysis was executed to assess the expression levels of HHLA2, density and spatial patterns of CD68&lt;sup&gt;+&lt;/sup&gt;HLA-DR&lt;sup&gt;+&lt;/sup&gt;CD163&lt;sup&gt;-&lt;/sup&gt; (M1 macrophages), CTLA-4&lt;sup&gt;+&lt;/sup&gt;CD4&lt;sup&gt;+&lt;/sup&gt;FoxP3&lt;sup&gt;+&lt;/sup&gt; (CTLA-4&lt;sup&gt;+&lt;/sup&gt;Treg cells), CTLA-4&lt;sup&gt;+&lt;/sup&gt;CD4&lt;sup&gt;+&lt;/sup&gt;FoxP3&lt;sup&gt;-&lt;/sup&gt; (CTLA-4&lt;sup&gt;+&lt;/sup&gt;Tcon cells), exhausted CD8&lt;sup&gt;+&lt;/sup&gt;T cells, and terminally exhausted CD8&lt;sup&gt;+&lt;/sup&gt;T cells in LSCC tissues. Survival analysis was conducted to evaluate the prognostic significance of HHLA2 and these immune checkpoints or immune cell populations, employing COX regression analysis to identify independent prognostic factors.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Kaplan-Meier (K-M) survival curves revealed a significant association between HHLA2 expression and overall survival (OS) in LSCC. Elevated levels of HHLA2 were linked to reduced patient survival, indicating its potential as a prognostic marker (HR: 3.230, 95%CI 0.9205-11.34, P = 0.0067). Notably, increased infiltration of CD68&lt;sup&gt;+&lt;/sup&gt; cells (total macrophages), STING&lt;sup&gt;+&lt;/sup&gt;CD68&lt;sup&gt;+&lt;/sup&gt;HLA-DR&lt;sup&gt;+&lt;/sup&gt;CD163&lt;sup&gt;-&lt;/sup&gt; (STING&lt;sup&gt;+&lt;/sup&gt;M1 macrophages), CTLA-4&lt;sup&gt;+&lt;/sup&gt;CD4&lt;sup&gt;+&lt;/sup&gt;FoxP3&lt;sup&gt;+&lt;/sup&gt;, CTLA-4&lt;sup&gt;+&lt;/sup&gt;CD4&lt;sup&gt;+&lt;/sup&gt;FoxP3&lt;sup&gt;-&lt;/sup&gt;, PD-1&lt;sup&gt;+&lt;/sup&gt;LAG-3&lt;sup&gt;+&lt;/sup&gt;CD8&lt;sup&gt;+&lt;/sup&gt;T cells, and PD-1&lt;sup&gt;+&lt;/sup&gt;LAG-3&lt;sup&gt;+&lt;/sup&gt;TIM-3&lt;sup&gt;+&lt;/sup&gt;CD8&lt;sup&gt;+&lt;/sup&gt;T cells strongly linked to poorer survival outcomes (P &lt; 0.05). A discernible trend was observed between the levels of these immune cell populations, STING&lt;sup&gt;+&lt;/sup&gt;CD68&lt;sup&gt;+&lt;/sup&gt; (STING&lt;sup&gt;+&lt;/sup&gt; total macrophages), CD68&lt;sup&gt;+&lt;/sup&gt;HLA-DR&lt;sup&gt;+&lt;/sup&gt;CD163&lt;sup&gt;-&lt;/sup&gt;, STING&lt;sup&gt;+&lt;/sup&gt;CD68&lt;sup&gt;+&lt;/sup&gt;CD163&lt;sup&gt;+&lt;/sup&gt;HLA-DR&lt;sup&gt;-&lt;/sup&gt; (STING&lt;sup&gt;+&lt;/sup&gt;M2 macrophages), PD-1&lt;sup&gt;+&lt;/sup&gt;LAG-3&lt;sup&gt;-&lt;/sup&gt;CD8&lt;sup&gt;+&lt;/sup&gt;T cells, PD-1&lt;sup&gt;+&lt;/sup&gt;TIM-3&lt;sup&gt;+&lt;/sup&gt;CD8&lt;sup&gt;+&lt;/sup&gt;T cells, and PD-1&lt;sup&gt;+&lt;/sup&gt;LAG-3&lt;sup&gt;+&lt;/sup&gt;TIM-3&lt;sup&gt;-&lt;/sup&gt;CD8&lt;sup&gt;+&lt;/sup&gt;T cells and prognosis. Importantly, multivariate COX analysis identified HHLA2 as an independent predictive factor for OS in LSCC patients (HR = 3.86, 95% CI 1.08-13.80, P = 0.038). This underscored the potential of HHLA2 as a c","PeriodicalId":9595,"journal":{"name":"Cancer Immunology, Immunotherapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deciphering the interplay of HPV infection, MHC-II expression, and CXCL13+ CD4+ T cell activation in oropharyngeal cancer: implications for immunotherapy. 解密口咽癌中 HPV 感染、MHC-II 表达和 CXCL13+ CD4+ T 细胞活化的相互作用:对免疫疗法的影响。
IF 4.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-08-06 DOI: 10.1007/s00262-024-03789-0
Shida Yan, Xing Zhang, Qiaohong Lin, Mingyuan Du, Yiqi Li, Shuai He, Jingtao Chen, Xiyuan Li, Jinxin Bei, Shuwei Chen, Ming Song

Background: Human papillomavirus (HPV) infection has become an important etiological driver of oropharyngeal squamous cell carcinoma (OPSCC), leading to unique tumor characteristics. However, the interplay between HPV-associated tumor cells and tumor microenvironment (TME) remains an enigma.

Methods: We performed a single-cell RNA-sequencing (scRNA-seq) on HPV-positive (HPV+) and HPV-negative (HPV) OPSCC tumors, each for three samples, and one normal tonsil tissue. Ex vivo validation assays including immunofluorescence staining, cell line co-culture, and flow cytometry analysis were used to test specific subtypes of HPV+ tumor cells and their communications with T cells.

Results: Through a comprehensive single-cell transcriptome analysis, we uncover the distinct transcriptional signatures between HPV+ and HPV OPSCC. Specifically, HPV+ OPSCC tumor cells manifest an enhanced interferon response and elevated expression of the major histocompatibility complex II (MHC-II), potentially bolstering tumor recognition and immune response. Furthermore, we identify a CXCL13+CD4+ T cell subset that exhibits dual features of both follicular and pro-inflammatory helper T cells. Noteworthily, HPV+ OPSCC tumor cells embrace extensive intercellular communications with CXCL13+CD4+ T cells. Interaction with HPV+ OPSCC tumor cells amplifies CXCL13 and IFNγ release in CD4+T cells, fostering a pro-inflammatory TME. Additionally, HPV+ tumor cells expressing high MHC-II and CXCL13+CD4+ T cell prevalence are indicative of favorable overall survival rates in OPSCC patients.

Conclusions: Together, our study underscores a synergistic inflammatory immune response orchestrated by highly immunogenic tumor cells and CXCL13+CD4+ T cells in HPV+ OPSCC, offering useful insights into strategy development for patient stratification and effective immunotherapy in OPSCC.

背景:人乳头状瘤病毒(HPV)感染已成为口咽鳞状细胞癌(OPSCC)的重要病因,导致其具有独特的肿瘤特征。然而,HPV相关肿瘤细胞与肿瘤微环境(TME)之间的相互作用仍然是一个谜:我们对 HPV 阳性(HPV+)和 HPV 阴性(HPV-)的 OPSCC 肿瘤(各三个样本)和一个正常扁桃体组织进行了单细胞 RNA 序列分析(scRNA-seq)。体内外验证试验包括免疫荧光染色、细胞系共培养和流式细胞仪分析,用于检测HPV+肿瘤细胞的特定亚型及其与T细胞的通讯:通过全面的单细胞转录组分析,我们发现了HPV+和HPV- OPSCC之间不同的转录特征。具体来说,HPV+ OPSCC肿瘤细胞的干扰素反应增强,主要组织相容性复合体II(MHC-II)表达升高,这可能会增强肿瘤识别和免疫反应。此外,我们还发现了一种 CXCL13+CD4+ T 细胞亚群,它同时表现出滤泡和促炎辅助 T 细胞的双重特征。值得注意的是,HPV+ OPSCC 肿瘤细胞与 CXCL13+CD4+ T 细胞之间有着广泛的细胞间通讯。与 HPV+ OPSCC 肿瘤细胞的相互作用扩大了 CD4+T 细胞中 CXCL13 和 IFNγ 的释放,促进了促炎性 TME 的形成。此外,表达高MHC-II和CXCL13+CD4+T细胞的HPV+肿瘤细胞表明OPSCC患者的总生存率较高:总之,我们的研究强调了高免疫原性肿瘤细胞和 CXCL13+CD4+ T 细胞在 HPV+ OPSCC 中协调的协同炎症免疫反应,为 OPSCC 患者分层和有效免疫疗法的策略制定提供了有益的启示。
{"title":"Deciphering the interplay of HPV infection, MHC-II expression, and CXCL13<sup>+</sup> CD4<sup>+</sup> T cell activation in oropharyngeal cancer: implications for immunotherapy.","authors":"Shida Yan, Xing Zhang, Qiaohong Lin, Mingyuan Du, Yiqi Li, Shuai He, Jingtao Chen, Xiyuan Li, Jinxin Bei, Shuwei Chen, Ming Song","doi":"10.1007/s00262-024-03789-0","DOIUrl":"10.1007/s00262-024-03789-0","url":null,"abstract":"<p><strong>Background: </strong>Human papillomavirus (HPV) infection has become an important etiological driver of oropharyngeal squamous cell carcinoma (OPSCC), leading to unique tumor characteristics. However, the interplay between HPV-associated tumor cells and tumor microenvironment (TME) remains an enigma.</p><p><strong>Methods: </strong>We performed a single-cell RNA-sequencing (scRNA-seq) on HPV-positive (HPV<sup>+</sup>) and HPV-negative (HPV<sup>‒</sup>) OPSCC tumors, each for three samples, and one normal tonsil tissue. Ex vivo validation assays including immunofluorescence staining, cell line co-culture, and flow cytometry analysis were used to test specific subtypes of HPV<sup>+</sup> tumor cells and their communications with T cells.</p><p><strong>Results: </strong>Through a comprehensive single-cell transcriptome analysis, we uncover the distinct transcriptional signatures between HPV<sup>+</sup> and HPV<sup>‒</sup> OPSCC. Specifically, HPV<sup>+</sup> OPSCC tumor cells manifest an enhanced interferon response and elevated expression of the major histocompatibility complex II (MHC-II), potentially bolstering tumor recognition and immune response. Furthermore, we identify a CXCL13<sup>+</sup>CD4<sup>+</sup> T cell subset that exhibits dual features of both follicular and pro-inflammatory helper T cells. Noteworthily, HPV<sup>+</sup> OPSCC tumor cells embrace extensive intercellular communications with CXCL13<sup>+</sup>CD4<sup>+</sup> T cells. Interaction with HPV<sup>+</sup> OPSCC tumor cells amplifies CXCL13 and IFNγ release in CD4<sup>+</sup>T cells, fostering a pro-inflammatory TME. Additionally, HPV<sup>+</sup> tumor cells expressing high MHC-II and CXCL13<sup>+</sup>CD4<sup>+</sup> T cell prevalence are indicative of favorable overall survival rates in OPSCC patients.</p><p><strong>Conclusions: </strong>Together, our study underscores a synergistic inflammatory immune response orchestrated by highly immunogenic tumor cells and CXCL13<sup>+</sup>CD4<sup>+</sup> T cells in HPV<sup>+</sup> OPSCC, offering useful insights into strategy development for patient stratification and effective immunotherapy in OPSCC.</p>","PeriodicalId":9595,"journal":{"name":"Cancer Immunology, Immunotherapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of the interval between neoadjuvant immunotherapy and surgery on prognosis in esophageal squamous cell carcinoma (ESCC): a real-world study. 食管鳞状细胞癌(ESCC)新辅助免疫疗法和手术之间的间隔对预后的影响:一项真实世界研究。
IF 4.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-08-06 DOI: 10.1007/s00262-024-03787-2
Guozhen Yang, Yutong Hong, Xiaomin Zhang, Chufeng Zeng, Linyu Tan, Xu Zhang

Background: The time interval between neoadjuvant immunotherapy and surgery is 6 weeks for esophageal squamous cell carcinoma (ESCC), but whether delayed surgery affects prognosis remains unclear.

Methods: Clinical data of locally advanced ESCC who underwent neoadjuvant immunotherapy followed by esophagectomy from November 2019 to December 2022 were collected. The surgery outcomes and prognosis were compared between short-interval (time to surgery ≤ 6 weeks) and long-interval groups (time to surgery > 6 weeks).

Results: 152 patients were enrolled totally, with a ratio of 91:61 between short-interval and long-interval groups. The rate of pathological complete response in the short-interval and long-interval groups were 34.1% and 24.6% (P = 0.257). Delayed surgery did not have a significantly impact on the number of lymph node dissections (P = 0.133), operative duration (P = 0.689), blood loss (P = 0.837), hospitalization duration (P = 0.293), chest drainage duration (P = 0.886) and postoperative complications (P > 0.050). The 3-year Overall survival (OS) rates were 85.10% in the short-interval group, and 82.07% in the long-interval group (P = 0.435). The 3-year disease-free survival (DFS) rates were 83.41% and 70.86% in the two groups (P = 0.037). Subgroup analysis revealed that patients with a favorable response to immunotherapy (tumor regression grade 0) exhibited inferior 3-year OS (long-interval vs. short-interval: 51.85% vs. 91.08%, P = 0.035) and DFS (long-interval vs. short-interval: 47.40% vs. 91.08%, P = 0.014) in the long-interval group.

Conclusions: Delayed surgery after neoadjuvant immunotherapy does not further improve pathological response; instead, it resulted in a poorer DFS. Especially for patients with a favorable response to immunotherapy, delayed surgery increases the risk of mortality and recurrence.

背景:食管鳞状细胞癌(ESCC)新辅助免疫疗法与手术之间的时间间隔为6周,但延迟手术是否会影响预后仍不清楚:食管鳞状细胞癌(ESCC)新辅助免疫治疗与手术之间的时间间隔为6周,但延迟手术是否会影响预后仍不清楚:收集了2019年11月至2022年12月期间接受新辅助免疫治疗后进行食管切除术的局部晚期ESCC患者的临床数据。比较短间隔组(手术时间≤6周)和长间隔组(手术时间>6周)的手术结果和预后:共有 152 名患者入组,短间隔组和长间隔组的比例为 91:61。短间隔组和长间隔组的病理完全反应率分别为 34.1%和 24.6%(P = 0.257)。延迟手术对淋巴结清扫次数(P = 0.133)、手术时间(P = 0.689)、失血量(P = 0.837)、住院时间(P = 0.293)、胸腔引流时间(P = 0.886)和术后并发症(P > 0.050)没有明显影响。短间隔组的 3 年总生存率(OS)为 85.10%,长间隔组为 82.07%(P = 0.435)。两组的3年无病生存率(DFS)分别为83.41%和70.86%(P = 0.037)。亚组分析显示,对免疫治疗反应良好(肿瘤消退等级为0)的患者,长间隔组的3年OS(长间隔组与短间隔组相比:51.85% vs. 91.08%,P = 0.035)和DFS(长间隔组与短间隔组相比:47.40% vs. 91.08%,P = 0.014)均低于短间隔组:结论:新辅助免疫疗法后延迟手术并不能进一步改善病理反应,反而会导致较差的 DFS。尤其是对免疫疗法反应良好的患者,延迟手术会增加死亡和复发的风险。
{"title":"Impact of the interval between neoadjuvant immunotherapy and surgery on prognosis in esophageal squamous cell carcinoma (ESCC): a real-world study.","authors":"Guozhen Yang, Yutong Hong, Xiaomin Zhang, Chufeng Zeng, Linyu Tan, Xu Zhang","doi":"10.1007/s00262-024-03787-2","DOIUrl":"10.1007/s00262-024-03787-2","url":null,"abstract":"<p><strong>Background: </strong>The time interval between neoadjuvant immunotherapy and surgery is 6 weeks for esophageal squamous cell carcinoma (ESCC), but whether delayed surgery affects prognosis remains unclear.</p><p><strong>Methods: </strong>Clinical data of locally advanced ESCC who underwent neoadjuvant immunotherapy followed by esophagectomy from November 2019 to December 2022 were collected. The surgery outcomes and prognosis were compared between short-interval (time to surgery ≤ 6 weeks) and long-interval groups (time to surgery > 6 weeks).</p><p><strong>Results: </strong>152 patients were enrolled totally, with a ratio of 91:61 between short-interval and long-interval groups. The rate of pathological complete response in the short-interval and long-interval groups were 34.1% and 24.6% (P = 0.257). Delayed surgery did not have a significantly impact on the number of lymph node dissections (P = 0.133), operative duration (P = 0.689), blood loss (P = 0.837), hospitalization duration (P = 0.293), chest drainage duration (P = 0.886) and postoperative complications (P > 0.050). The 3-year Overall survival (OS) rates were 85.10% in the short-interval group, and 82.07% in the long-interval group (P = 0.435). The 3-year disease-free survival (DFS) rates were 83.41% and 70.86% in the two groups (P = 0.037). Subgroup analysis revealed that patients with a favorable response to immunotherapy (tumor regression grade 0) exhibited inferior 3-year OS (long-interval vs. short-interval: 51.85% vs. 91.08%, P = 0.035) and DFS (long-interval vs. short-interval: 47.40% vs. 91.08%, P = 0.014) in the long-interval group.</p><p><strong>Conclusions: </strong>Delayed surgery after neoadjuvant immunotherapy does not further improve pathological response; instead, it resulted in a poorer DFS. Especially for patients with a favorable response to immunotherapy, delayed surgery increases the risk of mortality and recurrence.</p>","PeriodicalId":9595,"journal":{"name":"Cancer Immunology, Immunotherapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chimeric antigen receptor dendritic cells targeted delivery of a single tumoricidal factor for cancer immunotherapy. 嵌合抗原受体树突状细胞靶向输送单一杀瘤因子用于癌症免疫疗法。
IF 4.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-08-06 DOI: 10.1007/s00262-024-03788-1
Rong Duan, Philip Milton, Chutamath Sittplangkoon, Xin Liu, Zhining Sui, Brendan F Boyce, Zhenqiang Yao

Background: Chimeric antigen receptor (CAR)-T cells have been used to treat blood cancers by producing a wide variety of cytokines. However, they are not effective in treating solid cancers and can cause severe side-effects, including cytokine release syndrome. TNFα is a tumoricidal cytokine, but it markedly increases the protein levels of cIAP1 and cIAP2, the members of inhibitor of apoptosis protein (IAP) family of E3 ubiquitin ligase that limits caspase-induced apoptosis. Degradation of IAP proteins by an IAP antagonist does not effectively kill cancer cells but enables TNFα to strongly induce cancer cell apoptosis. It would be a promising approach to treat cancers by targeted delivery of TNFα through an inactive adoptive cell in combination with an IAP antagonist.

Methods: Human dendritic cells (DCs) were engineered to express a single tumoricidal factor, TNFα, and a membrane-anchored Mucin1 antibody scFv, named Mucin 1 directed DCs expressing TNFα (M-DCsTNF). The efficacy of M-DCsTNF in recognizing and treating breast cancer was tested in vitro and in vivo.

Results: Mucin1 was highly expressed on the surface of a wide range of human breast cancer cell lines. M-DCsTNF directly associated with MDA-MB-231 cells in the bone of NSG mice. M-DCsTNF plus an IAP antagonist, SM-164, but neither alone, markedly induce MDA-MB-231 breast cancer cell apoptosis, which was blocked by TNF antibody. Importantly, M-DCsTNF combined with SM-164, but not SM-164 alone, inhibited the growth of patient-derived breast cancer in NSG mice.

Conclusion: An adoptive cell targeting delivery of TNFα combined with an IAP antagonist is a novel effective approach to treat breast cancer and could be expanded to treat other solid cancers. Unlike CAR-T cell, this novel adoptive cell is not activated to produce a wide variety of cytokines, except for additional overexpressed TNF, and thus could avoid the severe side effects such as cytokine release syndrome.

背景:嵌合抗原受体(CAR)-T 细胞可产生多种细胞因子,用于治疗血癌。然而,它们在治疗实体瘤方面效果不佳,而且会导致严重的副作用,包括细胞因子释放综合征。TNFα 是一种杀伤肿瘤的细胞因子,但它会显著增加 cIAP1 和 cIAP2 的蛋白水平,cIAP1 和 cIAP2 是 E3 泛素连接酶凋亡抑制蛋白(IAP)家族的成员,可限制 Caspase 诱导的细胞凋亡。IAP 拮抗剂降解 IAP 蛋白并不能有效杀死癌细胞,却能使 TNFα 强力诱导癌细胞凋亡。方法:设计人树突状细胞(DCs),使其表达单一杀瘤因子 TNFα,并表达膜锚定 Mucin1 抗体 scFv,命名为 Mucin 1 定向表达 TNFα 的 DCs(M-DCsTNF)。研究人员在体外和体内测试了 M-DCsTNF 识别和治疗乳腺癌的功效:结果:Mucin1 在多种人类乳腺癌细胞系表面高度表达。M-DCsTNF可直接与NSG小鼠骨中的MDA-MB-231细胞结合。M-DCsTNF 加上 IAP 拮抗剂 SM-164,但两者都不能单独诱导 MDA-MB-231 乳腺癌细胞凋亡,而 TNF 抗体能阻止这种凋亡。重要的是,M-DCsTNF 联合 SM-164(而非单独 SM-164)可抑制患者来源的乳腺癌在 NSG 小鼠体内的生长:结论:TNFα与IAP拮抗剂结合的收养细胞靶向递送是治疗乳腺癌的一种新的有效方法,并可扩展到治疗其他实体癌。与 CAR-T 细胞不同的是,除了额外过表达的 TNF 外,这种新型收养细胞不会被激活以产生多种细胞因子,因此可以避免细胞因子释放综合征等严重副作用。
{"title":"Chimeric antigen receptor dendritic cells targeted delivery of a single tumoricidal factor for cancer immunotherapy.","authors":"Rong Duan, Philip Milton, Chutamath Sittplangkoon, Xin Liu, Zhining Sui, Brendan F Boyce, Zhenqiang Yao","doi":"10.1007/s00262-024-03788-1","DOIUrl":"10.1007/s00262-024-03788-1","url":null,"abstract":"<p><strong>Background: </strong>Chimeric antigen receptor (CAR)-T cells have been used to treat blood cancers by producing a wide variety of cytokines. However, they are not effective in treating solid cancers and can cause severe side-effects, including cytokine release syndrome. TNFα is a tumoricidal cytokine, but it markedly increases the protein levels of cIAP1 and cIAP2, the members of inhibitor of apoptosis protein (IAP) family of E3 ubiquitin ligase that limits caspase-induced apoptosis. Degradation of IAP proteins by an IAP antagonist does not effectively kill cancer cells but enables TNFα to strongly induce cancer cell apoptosis. It would be a promising approach to treat cancers by targeted delivery of TNFα through an inactive adoptive cell in combination with an IAP antagonist.</p><p><strong>Methods: </strong>Human dendritic cells (DCs) were engineered to express a single tumoricidal factor, TNFα, and a membrane-anchored Mucin1 antibody scFv, named Mucin 1 directed DCs expressing TNFα (M-DCs<sup>TNF</sup>). The efficacy of M-DCs<sup>TNF</sup> in recognizing and treating breast cancer was tested in vitro and in vivo.</p><p><strong>Results: </strong>Mucin1 was highly expressed on the surface of a wide range of human breast cancer cell lines. M-DCs<sup>TNF</sup> directly associated with MDA-MB-231 cells in the bone of NSG mice. M-DCs<sup>TNF</sup> plus an IAP antagonist, SM-164, but neither alone, markedly induce MDA-MB-231 breast cancer cell apoptosis, which was blocked by TNF antibody. Importantly, M-DCs<sup>TNF</sup> combined with SM-164, but not SM-164 alone, inhibited the growth of patient-derived breast cancer in NSG mice.</p><p><strong>Conclusion: </strong>An adoptive cell targeting delivery of TNFα combined with an IAP antagonist is a novel effective approach to treat breast cancer and could be expanded to treat other solid cancers. Unlike CAR-T cell, this novel adoptive cell is not activated to produce a wide variety of cytokines, except for additional overexpressed TNF, and thus could avoid the severe side effects such as cytokine release syndrome.</p>","PeriodicalId":9595,"journal":{"name":"Cancer Immunology, Immunotherapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical features associated with immune checkpoint inhibitor nephritis: a single-center clinical case series. 与免疫检查点抑制剂肾炎相关的临床特征:单中心临床病例系列。
IF 4.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-08-06 DOI: 10.1007/s00262-024-03775-6
Ramya Muddasani, Neel Talwar, Isa Mambetsariev, Jeremy Fricke, Mercury Lin, Daniel Schmolze, Andrew Yue, Amna Rizvi, Ravi Salgia

Background: Acute kidney injury (AKI) has been well described as a complication of immune checkpoint inhibitor therapy. We present a series of patients, the majority with lung adenocarcinoma, who developed AKI while actively receiving immune checkpoint inhibitors.

Methods: This is a retrospectively analyzed clinical case series of six patients treated at City of Hope Comprehensive Cancer Center. Data were collected on gender, age, ethnicity, comorbidities, concomitant medications, type of malignancy, treatments, and renal function. All patients underwent renal biopsy for classification of the mechanism of AKI. Comprehensive genomic profiling (CGP) was performed on tumor tissue for all patients.

Results: Patterns of AKI included acute interstitial nephritis and acute tubular necrosis. Contributing factors included the use of concomitant medications known to contribute to AKI. All but two patients had full resolution of the AKI with the use of steroids. There were several mutations found on CGP that was notable including an Exon 20 insertion as well as multiple NF1 and TP53 mutations. There was high PD-L1 expression on tumor tissue noted in two out of six patients. In addition to AKI, a subset of patients had proteinuria with biopsies revealing corresponding glomerular lesions of minimal change disease and focal and segmental glomerulosclerosis.

Conclusions: Our case series demonstrates that AKI from immune checkpoint inhibitors has a variable presentation that may require an individualized treatment approach. Further studies are needed to identify biomarkers that may help identify those at risk and guide the management of this condition.

背景:急性肾损伤(AKI)作为免疫检查点抑制剂治疗的一种并发症已被广泛描述。我们介绍了一系列在积极接受免疫检查点抑制剂治疗期间出现急性肾损伤的患者,其中大部分患者为肺腺癌患者:这是一个回顾性分析的临床病例系列,涉及在希望之城综合癌症中心接受治疗的六名患者。收集的数据包括性别、年龄、种族、合并症、伴随药物、恶性肿瘤类型、治疗方法和肾功能。所有患者都接受了肾活检,以便对 AKI 的机制进行分类。对所有患者的肿瘤组织进行了全面基因组分析(CGP):结果:AKI的模式包括急性间质性肾炎和急性肾小管坏死。诱发因素包括同时使用已知会导致 AKI 的药物。除两名患者外,所有患者在使用类固醇后都完全缓解了AKI。CGP上发现了几个值得注意的突变,包括一个外显子20插入以及多个NF1和TP53突变。六名患者中有两名患者的肿瘤组织中出现了 PD-L1 高表达。除了 AKI 外,部分患者还出现蛋白尿,活检显示相应的肾小球病变,包括微小病变、局灶性和节段性肾小球硬化:我们的系列病例表明,免疫检查点抑制剂引起的 AKI 表现各异,可能需要个体化的治疗方法。还需要进一步研究来确定生物标志物,以帮助识别高危人群并指导该病症的治疗。
{"title":"Clinical features associated with immune checkpoint inhibitor nephritis: a single-center clinical case series.","authors":"Ramya Muddasani, Neel Talwar, Isa Mambetsariev, Jeremy Fricke, Mercury Lin, Daniel Schmolze, Andrew Yue, Amna Rizvi, Ravi Salgia","doi":"10.1007/s00262-024-03775-6","DOIUrl":"10.1007/s00262-024-03775-6","url":null,"abstract":"<p><strong>Background: </strong>Acute kidney injury (AKI) has been well described as a complication of immune checkpoint inhibitor therapy. We present a series of patients, the majority with lung adenocarcinoma, who developed AKI while actively receiving immune checkpoint inhibitors.</p><p><strong>Methods: </strong>This is a retrospectively analyzed clinical case series of six patients treated at City of Hope Comprehensive Cancer Center. Data were collected on gender, age, ethnicity, comorbidities, concomitant medications, type of malignancy, treatments, and renal function. All patients underwent renal biopsy for classification of the mechanism of AKI. Comprehensive genomic profiling (CGP) was performed on tumor tissue for all patients.</p><p><strong>Results: </strong>Patterns of AKI included acute interstitial nephritis and acute tubular necrosis. Contributing factors included the use of concomitant medications known to contribute to AKI. All but two patients had full resolution of the AKI with the use of steroids. There were several mutations found on CGP that was notable including an Exon 20 insertion as well as multiple NF1 and TP53 mutations. There was high PD-L1 expression on tumor tissue noted in two out of six patients. In addition to AKI, a subset of patients had proteinuria with biopsies revealing corresponding glomerular lesions of minimal change disease and focal and segmental glomerulosclerosis.</p><p><strong>Conclusions: </strong>Our case series demonstrates that AKI from immune checkpoint inhibitors has a variable presentation that may require an individualized treatment approach. Further studies are needed to identify biomarkers that may help identify those at risk and guide the management of this condition.</p>","PeriodicalId":9595,"journal":{"name":"Cancer Immunology, Immunotherapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial. 转移性胰腺癌二线治疗中的低分次放疗加 PD-1 抗体和 SOX 化疗:单臂 II 期临床试验。
IF 4.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-08-06 DOI: 10.1007/s00262-024-03744-z
Qin Wang, Fan Tong, Li Qiao, Liang Qi, Yi Sun, Yahui Zhu, Jiayao Ni, Juan Liu, Weiwei Kong, Baorui Liu, Juan Du

Purpose: To assess the efficacy and safety of concurrent hypofractionated radiotherapy plus anti-PD-1 antibody and SOX chemotherapy in the treatment of metastatic pancreatic cancer (mPC) after failure of first-line chemotherapy.

Methods: Patients with pathologically confirmed mPC who failed standard first-line chemotherapy were enrolled. The patients were treated with a regimen of hypofractionated radiotherapy, SOX chemotherapy, and immune checkpoint inhibitors at our institution. We collected the patients' clinical information and outcome measurements. The median progression-free survival (mPFS) was the primary endpoint of the study, followed by disease control rate (DCR), objective response rate (ORR), median overall survival (mOS) and safety. Exploratory analyses included biomarkers related to the benefits.

Results: Between February 24, 2021, and August 30, 2023, twenty-five patients were enrolled in the study, and twenty-three patients who received at least one dose of the study agent had objective efficacy evaluation. The mPFS was 5.48 months, the mOS was 6.57 months, and the DCR and ORR were 69.5% and 30.4%, respectively. Among the seven patients who achieved a PR, the median duration of the response was 7.41 months. On-treatment decreased serum CA19-9 levels were associated with better overall survival. Besides, pretreatment inflammatory markers were associated with tumor response and survival.

Conclusions: Clinically meaningful antitumor activity and favorable safety profiles were demonstrated after treatment with these combination therapies in patients with refractory mPC. On-treatment decreased serum CA19-9 levels and pretreatment inflammatory markers platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), lactate dehydrogenase (LDH) might be biomarkers related to clinical benefits.

Clinical trial registration: https://www.chictr.org.cn/showproj.html?proj=130211 , identifier: ChiCTR2100049799, date of registration: 2021-08-09.

目的:评估低分次放疗联合抗PD-1抗体和SOX化疗治疗一线化疗失败后的转移性胰腺癌(mPC)的有效性和安全性:入选患者均为病理确诊的转移性胰腺癌患者,且一线化疗失败。这些患者在我院接受了低分次放疗、SOX化疗和免疫检查点抑制剂治疗。我们收集了患者的临床信息和疗效测量结果。中位无进展生存期(mPFS)是研究的主要终点,其次是疾病控制率(DCR)、客观反应率(ORR)、中位总生存期(mOS)和安全性。探索性分析包括与获益相关的生物标志物:2021年2月24日至2023年8月30日期间,共有25名患者入组研究,23名接受了至少一剂研究药物的患者进行了客观疗效评估。mPFS为5.48个月,mOS为6.57个月,DCR和ORR分别为69.5%和30.4%。在获得 PR 的 7 名患者中,中位反应持续时间为 7.41 个月。治疗时血清CA19-9水平的降低与较好的总生存率相关。此外,治疗前的炎症标志物与肿瘤反应和生存期有关:结论:对于难治性mPC患者,这些联合疗法具有临床意义的抗肿瘤活性和良好的安全性。治疗时血清CA19-9水平的降低和治疗前炎症标志物血小板与淋巴细胞比值(PLR)、淋巴细胞与单核细胞比值(LMR)、乳酸脱氢酶(LDH)可能是与临床获益相关的生物标志物。临床试验注册:https://www.chictr.org.cn/showproj.html?proj=130211 ,标识符:ChiCTR2100049799:ChiCTR2100049799,注册日期:2021-08-09。
{"title":"Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial.","authors":"Qin Wang, Fan Tong, Li Qiao, Liang Qi, Yi Sun, Yahui Zhu, Jiayao Ni, Juan Liu, Weiwei Kong, Baorui Liu, Juan Du","doi":"10.1007/s00262-024-03744-z","DOIUrl":"10.1007/s00262-024-03744-z","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the efficacy and safety of concurrent hypofractionated radiotherapy plus anti-PD-1 antibody and SOX chemotherapy in the treatment of metastatic pancreatic cancer (mPC) after failure of first-line chemotherapy.</p><p><strong>Methods: </strong>Patients with pathologically confirmed mPC who failed standard first-line chemotherapy were enrolled. The patients were treated with a regimen of hypofractionated radiotherapy, SOX chemotherapy, and immune checkpoint inhibitors at our institution. We collected the patients' clinical information and outcome measurements. The median progression-free survival (mPFS) was the primary endpoint of the study, followed by disease control rate (DCR), objective response rate (ORR), median overall survival (mOS) and safety. Exploratory analyses included biomarkers related to the benefits.</p><p><strong>Results: </strong>Between February 24, 2021, and August 30, 2023, twenty-five patients were enrolled in the study, and twenty-three patients who received at least one dose of the study agent had objective efficacy evaluation. The mPFS was 5.48 months, the mOS was 6.57 months, and the DCR and ORR were 69.5% and 30.4%, respectively. Among the seven patients who achieved a PR, the median duration of the response was 7.41 months. On-treatment decreased serum CA19-9 levels were associated with better overall survival. Besides, pretreatment inflammatory markers were associated with tumor response and survival.</p><p><strong>Conclusions: </strong>Clinically meaningful antitumor activity and favorable safety profiles were demonstrated after treatment with these combination therapies in patients with refractory mPC. On-treatment decreased serum CA19-9 levels and pretreatment inflammatory markers platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), lactate dehydrogenase (LDH) might be biomarkers related to clinical benefits.</p><p><strong>Clinical trial registration: </strong>https://www.chictr.org.cn/showproj.html?proj=130211 , identifier: ChiCTR2100049799, date of registration: 2021-08-09.</p>","PeriodicalId":9595,"journal":{"name":"Cancer Immunology, Immunotherapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors. 用于治疗晚期实体瘤的人类白细胞抗原-G (HLA-G) x CD3 双特异性抗体 JNJ-78306358 的安全性和临床活性。
IF 4.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-08-06 DOI: 10.1007/s00262-024-03790-7
Ravit Geva, Maria Vieito, Jorge Ramon, Ruth Perets, Manuel Pedregal, Elena Corral, Bernard Doger, Emiliano Calvo, Jorge Bardina, Elena Garralda, Regina J Brown, James G Greger, Shujian Wu, Douglas Steinbach, Tsun-Wen Sheena Yao, Yu Cao, Josh Lauring, Ruchi Chaudhary, Jaymala Patel, Bharvin Patel, Victor Moreno

Background: JNJ-78306358 is a bispecific antibody that redirects T cells to kill human leukocyte antigen-G (HLA-G)-expressing tumor cells. This dose escalation study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of JNJ-78306358 in patients with advanced solid tumors.

Methods: Adult patients with metastatic/unresectable solid tumors with high prevalence of HLA-G expression were enrolled. Dose escalation was initiated with once-weekly subcutaneous administration with step-up dosing to mitigate cytokine release syndrome (CRS).

Results: Overall, 39 heavily pretreated patients (colorectal cancer: n = 23, ovarian cancer: n = 10, and renal cell carcinoma: n = 6) were dosed in 7 cohorts. Most patients (94.9%) experienced ≥ 1 treatment-emergent adverse events (TEAEs); 87.2% had ≥ 1 related TEAEs. About half of the patients (48.7%) experienced CRS, which were grade 1/2. Nine patients (23.1%) received tocilizumab for CRS. No grade 3 CRS was observed. Dose-limiting toxicities (DLTs) of increased transaminases, pneumonitis and recurrent CRS requiring a dose reduction were reported in 4 patients, coinciding with CRS. No treatment-related deaths reported. No objective responses were noted, but 2 patients had stable disease > 40 weeks. JNJ-78306358 stimulated peripheral T cell activation and cytokine release. Anti-drug antibodies were observed in 45% of evaluable patients with impact on exposure. Approximately half of archival tumor samples (48%) had expression of HLA-G by immunohistochemistry.

Conclusion: JNJ-78306358 showed pharmacodynamic effects with induction of cytokines and T cell activation. JNJ-78306358 was associated with CRS-related toxicities including increased transaminases and pneumonitis which limited its dose escalation to potentially efficacious levels. Trial registration number ClinicalTrials.gov (No. NCT04991740).

背景:JNJ-78306358是一种双特异性抗体,它能引导T细胞杀死表达人类白细胞抗原-G(HLA-G)的肿瘤细胞。这项剂量递增研究评估了 JNJ-78306358 在晚期实体瘤患者中的安全性、药代动力学、药效学和初步抗肿瘤活性:方法:研究人员招募了患有转移性/不可切除实体瘤且HLA-G表达率较高的成年患者。开始剂量升级,每周一次皮下注射,同时加大剂量以减轻细胞因子释放综合征(CRS):共有 39 名重度预处理患者(结直肠癌:23 人;卵巢癌:10 人;肾细胞癌:6 人)在 7 个队列中接受了治疗。大多数患者(94.9%)发生了≥1次治疗突发不良事件(TEAEs);87.2%发生了≥1次相关TEAEs。约半数患者(48.7%)出现了CRS,均为1/2级。9名患者(23.1%)因CRS接受了托珠单抗治疗。未观察到 3 级 CRS。有4名患者报告了转氨酶升高、肺炎和复发性CRS等剂量限制性毒性(DLTs),需要减少剂量,并与CRS同时发生。没有与治疗相关的死亡报告。未发现客观反应,但有 2 名患者病情稳定超过 40 周。JNJ-78306358 可刺激外周 T 细胞活化和细胞因子释放。在 45% 的可评估患者中观察到了抗药性抗体,并对暴露产生了影响。约有一半的存档肿瘤样本(48%)通过免疫组化表达了 HLA-G:结论:JNJ-78306358 具有诱导细胞因子和 T 细胞活化的药效学效应。JNJ-78306358与CRS相关毒性有关,包括转氨酶升高和肺炎,这限制了其剂量升级到潜在有效水平。试验注册号为 ClinicalTrials.gov(NCT04991740 号)。
{"title":"Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors.","authors":"Ravit Geva, Maria Vieito, Jorge Ramon, Ruth Perets, Manuel Pedregal, Elena Corral, Bernard Doger, Emiliano Calvo, Jorge Bardina, Elena Garralda, Regina J Brown, James G Greger, Shujian Wu, Douglas Steinbach, Tsun-Wen Sheena Yao, Yu Cao, Josh Lauring, Ruchi Chaudhary, Jaymala Patel, Bharvin Patel, Victor Moreno","doi":"10.1007/s00262-024-03790-7","DOIUrl":"10.1007/s00262-024-03790-7","url":null,"abstract":"<p><strong>Background: </strong>JNJ-78306358 is a bispecific antibody that redirects T cells to kill human leukocyte antigen-G (HLA-G)-expressing tumor cells. This dose escalation study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of JNJ-78306358 in patients with advanced solid tumors.</p><p><strong>Methods: </strong>Adult patients with metastatic/unresectable solid tumors with high prevalence of HLA-G expression were enrolled. Dose escalation was initiated with once-weekly subcutaneous administration with step-up dosing to mitigate cytokine release syndrome (CRS).</p><p><strong>Results: </strong>Overall, 39 heavily pretreated patients (colorectal cancer: n = 23, ovarian cancer: n = 10, and renal cell carcinoma: n = 6) were dosed in 7 cohorts. Most patients (94.9%) experienced ≥ 1 treatment-emergent adverse events (TEAEs); 87.2% had ≥ 1 related TEAEs. About half of the patients (48.7%) experienced CRS, which were grade 1/2. Nine patients (23.1%) received tocilizumab for CRS. No grade 3 CRS was observed. Dose-limiting toxicities (DLTs) of increased transaminases, pneumonitis and recurrent CRS requiring a dose reduction were reported in 4 patients, coinciding with CRS. No treatment-related deaths reported. No objective responses were noted, but 2 patients had stable disease > 40 weeks. JNJ-78306358 stimulated peripheral T cell activation and cytokine release. Anti-drug antibodies were observed in 45% of evaluable patients with impact on exposure. Approximately half of archival tumor samples (48%) had expression of HLA-G by immunohistochemistry.</p><p><strong>Conclusion: </strong>JNJ-78306358 showed pharmacodynamic effects with induction of cytokines and T cell activation. JNJ-78306358 was associated with CRS-related toxicities including increased transaminases and pneumonitis which limited its dose escalation to potentially efficacious levels. Trial registration number ClinicalTrials.gov (No. NCT04991740).</p>","PeriodicalId":9595,"journal":{"name":"Cancer Immunology, Immunotherapy","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Immunology, Immunotherapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1